Capsugel To Acquire Bend Research - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Capsugel To Acquire Bend Research


Seeking to build its bioavailability-enhancement capabilities, Capsugel, a provider of capsules and formulation-development and manufacturing services, has agreed to acquire the CDMO Bend Research. Bend Research will become part of Capsugel’s Dosage Form Solutions (DFS) business unit. The deal, which is subject to customary closing conditions, including approval from regulatory authorities, is expected to occur within the next 30 days. Terms of the transaction were not disclosed. 

“The Bend Research transaction highlights Capsugel’s commitment to investment and strategic growth since becoming a KKR portfolio company in the 2011 carve-out acquisition from Pfizer,” said Guido Driesen, president and CEO of Capsugel, in a Sept. 5, 2013 company press release. “Capsugel and Bend Research share common foundations in science and engineering, with values centered on innovation, quality and customer service.”

Bend Research, headquartered in Bend Oregon, has capabilities in bioavailability enhancement, particularly through spray-dried dispersion (SDD) formulation technology. It also offers other drug-delivery technologies, including solutions for modified release, inhalation delivery, and biotherapeutic processing and formulation.

This is the second acquisition for Capsugel in 2013.  In March 2013, it acquired acquired Encap Drug Delivery, a CDMO based in Scotland, focused on liquid and semisolid encapsulation-based product development and clinical and commercial manufacturing. In February 2013, Capsugel launched its DSF business unit to focus on lipid-based formulations and expand its offerings in targeted-release capsules.  In June 2013, Capsugel launched its LIPIDEX technology platform, which integrates the company’s lipid, liquid, and semisolid fill technologies, product development experience, and commercial manufacturing infrastructure to support the DFS business unit.

Source: Capsugel

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
38%
Breakthrough designations
13%
Protecting the supply chain
38%
Expedited reviews of drug submissions
13%
More stakeholder involvement
0%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
USP Faces New Challenges

Click here